News | November 23, 2023
Lupin launches Vilfuro-G for COPD Management in India
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Animations, colors, and shapes help to improve poor situational awareness, which is responsible for 81.5% of anesthesia-related errors
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
The Main campaign started from October 2
Apollo Telehealth has established more than 700 centers, in 7 states
Public private partnership (PPP) with integrated strategy essential to achieve ‘TB Mukt Bharat’ by 2025
Subscribe To Our Newsletter & Stay Updated
